Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01216163 · ClinicalTrials.gov registry record · Phase 3

Study Evaluating A Novel Ibuprofen Formulation In The Treatment Of Dental Pain

A Phase 3 study of Pain, sponsored by Pfizer.

Completed
Registry status
Phase 3
Development phase
218
Enrollment target
1
Study location

NCT01216163 is a Phase 3 study of Pain that has completed, run by Pfizer. The registered enrollment target is 218 participants, below the 304-participant average among 374 other Pain trials with a reported enrollment target (28% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01216163, a Phase 3 study of Pain, has completed, sponsored by Pfizer.

COMPLETED
Registry status
Phase 3
Development phase
218 participants
Enrollment target
1
Study location

Study Summary

This study will compare the analgesic efficacy of a single-dose of a novel ibuprofen formulation to placebo and acetaminophen in the treatment of post-surgical dental pain following "wisdom" tooth (third molar) removal.

Conditions Studied

Interventions

  • DRUG Placebo
  • DRUG Acetaminophen
  • DRUG Novel Ibuprofen

Study Locations (1)

Utah

  • Pfizer Investigational Site - Salt Lake City

Trial Details

FieldValue
Enrollment Target 218 participants
Start Date 2010-10
Est. Completion 2011-01
Phase Phase 3

Sponsor

Pfizer

1,845 total trials

What the Registry Record Tells You About NCT01216163

The ClinicalTrials.gov registry entry for NCT01216163 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 218 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 304-participant average among 374 other Pain trials with a reported enrollment target (28% lower). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Pain appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.

NCT01216163 reports 1 study location spanning 1 distinct geographic area - top geographies include Utah.

Frequently Asked Questions

What is clinical trial NCT01216163 about?

NCT01216163 is a clinical study titled "Study Evaluating A Novel Ibuprofen Formulation In The Treatment Of Dental Pain". This study will compare the analgesic efficacy of a single-dose of a novel ibuprofen formulation to placebo and acetaminophen in the treatment of post-surgical dental pain following "wisdom" tooth (third molar) removal.

What is the current status of trial NCT01216163?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 218 participants. The study started on 2010-10. Estimated completion is 2011-01.

What conditions does trial NCT01216163 study?

This clinical trial studies the following conditions: Pain.

What interventions are being tested in trial NCT01216163?

The interventions under investigation include: Placebo (DRUG), Acetaminophen (DRUG), Novel Ibuprofen (DRUG).

Who is sponsoring clinical trial NCT01216163?

This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01216163 being conducted?

This trial has 1 study location across Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Pain

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.